Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.

Hiroaki TaniokaMichitaka HondaChihiro TanakaYoshitaka MoritaKeiichiro IshibashiTakeshi KatoChu MatsudaMasato KataokaHironaga SatakeYoshinori MunemotoKenji KobayashiMasazumi TakahashiKen NakataJunichi SakamotoKoji ObaHideyuki Mishima

Published in: International journal of clinical oncology (2019)

Biweekly SOX regimen with reintroduction of oxaliplatin could be exploitable as the third- and/or later-line treatments for patients with mCRC.

Keyphrases

phase ii study
transcription factor
stem cells

open label
squamous cell carcinoma
small cell lung cancer

locally advanced
clinical trial

rectal cancer
newly diagnosed